Cargando…
Intratumor heterogeneity and cell secretome promote chemotherapy resistance and progression of colorectal cancer
The major underlying cause for the high mortality rate in colorectal cancer (CRC) relies on its drug resistance, to which intratumor heterogeneity (ITH) contributes substantially. CRC tumors have been reported to comprise heterogeneous populations of cancer cells that can be grouped into 4 consensus...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10160076/ https://www.ncbi.nlm.nih.gov/pubmed/37142595 http://dx.doi.org/10.1038/s41419-023-05806-z |
_version_ | 1785037208744361984 |
---|---|
author | Källberg, Julia Harrison, Alexandra March, Valerie Bērziņa, Santa Nemazanyy, Ivan Kepp, Oliver Kroemer, Guido Mouillet-Richard, Sophie Laurent-Puig, Pierre Taly, Valérie Xiao, Wenjin |
author_facet | Källberg, Julia Harrison, Alexandra March, Valerie Bērziņa, Santa Nemazanyy, Ivan Kepp, Oliver Kroemer, Guido Mouillet-Richard, Sophie Laurent-Puig, Pierre Taly, Valérie Xiao, Wenjin |
author_sort | Källberg, Julia |
collection | PubMed |
description | The major underlying cause for the high mortality rate in colorectal cancer (CRC) relies on its drug resistance, to which intratumor heterogeneity (ITH) contributes substantially. CRC tumors have been reported to comprise heterogeneous populations of cancer cells that can be grouped into 4 consensus molecular subtypes (CMS). However, the impact of inter-cellular interaction between these cellular states on the emergence of drug resistance and CRC progression remains elusive. Here, we explored the interaction between cell lines belonging to the CMS1 (HCT116 and LoVo) and the CMS4 (SW620 and MDST8) in a 3D coculture model, mimicking the ITH of CRC. The spatial distribution of each cell population showed that CMS1 cells had a preference to grow in the center of cocultured spheroids, while CMS4 cells localized at the periphery, in line with observations in tumors from CRC patients. Cocultures of CMS1 and CMS4 cells did not alter cell growth, but significantly sustained the survival of both CMS1 and CMS4 cells in response to the front-line chemotherapeutic agent 5-fluorouracil (5-FU). Mechanistically, the secretome of CMS1 cells exhibited a remarkable protective effect for CMS4 cells against 5-FU treatment, while promoting cellular invasion. Secreted metabolites may be responsible for these effects, as demonstrated by the existence of 5-FU induced metabolomic shifts, as well as by the experimental transfer of the metabolome between CMS1 and CMS4 cells. Overall, our results suggest that the interplay between CMS1 and CMS4 cells stimulates CRC progression and reduces the efficacy of chemotherapy. |
format | Online Article Text |
id | pubmed-10160076 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-101600762023-05-06 Intratumor heterogeneity and cell secretome promote chemotherapy resistance and progression of colorectal cancer Källberg, Julia Harrison, Alexandra March, Valerie Bērziņa, Santa Nemazanyy, Ivan Kepp, Oliver Kroemer, Guido Mouillet-Richard, Sophie Laurent-Puig, Pierre Taly, Valérie Xiao, Wenjin Cell Death Dis Article The major underlying cause for the high mortality rate in colorectal cancer (CRC) relies on its drug resistance, to which intratumor heterogeneity (ITH) contributes substantially. CRC tumors have been reported to comprise heterogeneous populations of cancer cells that can be grouped into 4 consensus molecular subtypes (CMS). However, the impact of inter-cellular interaction between these cellular states on the emergence of drug resistance and CRC progression remains elusive. Here, we explored the interaction between cell lines belonging to the CMS1 (HCT116 and LoVo) and the CMS4 (SW620 and MDST8) in a 3D coculture model, mimicking the ITH of CRC. The spatial distribution of each cell population showed that CMS1 cells had a preference to grow in the center of cocultured spheroids, while CMS4 cells localized at the periphery, in line with observations in tumors from CRC patients. Cocultures of CMS1 and CMS4 cells did not alter cell growth, but significantly sustained the survival of both CMS1 and CMS4 cells in response to the front-line chemotherapeutic agent 5-fluorouracil (5-FU). Mechanistically, the secretome of CMS1 cells exhibited a remarkable protective effect for CMS4 cells against 5-FU treatment, while promoting cellular invasion. Secreted metabolites may be responsible for these effects, as demonstrated by the existence of 5-FU induced metabolomic shifts, as well as by the experimental transfer of the metabolome between CMS1 and CMS4 cells. Overall, our results suggest that the interplay between CMS1 and CMS4 cells stimulates CRC progression and reduces the efficacy of chemotherapy. Nature Publishing Group UK 2023-05-05 /pmc/articles/PMC10160076/ /pubmed/37142595 http://dx.doi.org/10.1038/s41419-023-05806-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Källberg, Julia Harrison, Alexandra March, Valerie Bērziņa, Santa Nemazanyy, Ivan Kepp, Oliver Kroemer, Guido Mouillet-Richard, Sophie Laurent-Puig, Pierre Taly, Valérie Xiao, Wenjin Intratumor heterogeneity and cell secretome promote chemotherapy resistance and progression of colorectal cancer |
title | Intratumor heterogeneity and cell secretome promote chemotherapy resistance and progression of colorectal cancer |
title_full | Intratumor heterogeneity and cell secretome promote chemotherapy resistance and progression of colorectal cancer |
title_fullStr | Intratumor heterogeneity and cell secretome promote chemotherapy resistance and progression of colorectal cancer |
title_full_unstemmed | Intratumor heterogeneity and cell secretome promote chemotherapy resistance and progression of colorectal cancer |
title_short | Intratumor heterogeneity and cell secretome promote chemotherapy resistance and progression of colorectal cancer |
title_sort | intratumor heterogeneity and cell secretome promote chemotherapy resistance and progression of colorectal cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10160076/ https://www.ncbi.nlm.nih.gov/pubmed/37142595 http://dx.doi.org/10.1038/s41419-023-05806-z |
work_keys_str_mv | AT kallbergjulia intratumorheterogeneityandcellsecretomepromotechemotherapyresistanceandprogressionofcolorectalcancer AT harrisonalexandra intratumorheterogeneityandcellsecretomepromotechemotherapyresistanceandprogressionofcolorectalcancer AT marchvalerie intratumorheterogeneityandcellsecretomepromotechemotherapyresistanceandprogressionofcolorectalcancer AT berzinasanta intratumorheterogeneityandcellsecretomepromotechemotherapyresistanceandprogressionofcolorectalcancer AT nemazanyyivan intratumorheterogeneityandcellsecretomepromotechemotherapyresistanceandprogressionofcolorectalcancer AT keppoliver intratumorheterogeneityandcellsecretomepromotechemotherapyresistanceandprogressionofcolorectalcancer AT kroemerguido intratumorheterogeneityandcellsecretomepromotechemotherapyresistanceandprogressionofcolorectalcancer AT mouilletrichardsophie intratumorheterogeneityandcellsecretomepromotechemotherapyresistanceandprogressionofcolorectalcancer AT laurentpuigpierre intratumorheterogeneityandcellsecretomepromotechemotherapyresistanceandprogressionofcolorectalcancer AT talyvalerie intratumorheterogeneityandcellsecretomepromotechemotherapyresistanceandprogressionofcolorectalcancer AT xiaowenjin intratumorheterogeneityandcellsecretomepromotechemotherapyresistanceandprogressionofcolorectalcancer |